Multiple Sclerosis Drugs Market By Drug Class (Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, Interferon β Monoclonal Antibodies, Pyrimidine Synthesis Inhibitors, and Others), By Route of Administration (Oral and Injectable), By Distribution Channels (Retail Pharmacies, E-Commerce, and Hospital Pharmacies), Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018-2026

Market Definition

Global multiple sclerosis drugs market is estimated to reach $29.46 billion by 2026; growing at a CAGR of 6.3% till 2026. Multiple sclerosis (MS) is an auto-immune inflammatory disorder of the central nervous system (CNS) that results in the degeneration of nerves in the spinal cord and brain. Further, the immune system of MS patients fights their body cells that cause progressive damages in the brain and spinal cord. Symptoms of MS patients include blurred vision, inappropriate speaking and walking, problems associated with bowel and bladder, and others. Available treatment in the market for MS patients improves the overall quality of life with minimization of long term disability. Physical exercises coupled with cognitive, speech, and occupational helps to improve function. The major aspect that is triggering the multiple sclerosis drug market is the rising popularity of multiple sclerosis patients in some countries and high treatment compliance across the globe.

Market Determinants

Growing demand from expensive multiple sclerosis drugs and increased research in the field of MS to develop innovative therapies are key driving factors of the market. Moreover, extensive research and development activities further fuel market growth. However, the high cost of MS drugs and the non-availability of drugs are the factors manifesting as a major obstruct in the multiple sclerosis drug market. Moreover, advancements in biomedical science and mergers and acquisitions among top manufacturing companies would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global multiple sclerosis drugs market is mainly classified based on drug class, route of administration, and distribution channels. The drug class is further segmented into sphingosine 1 phosphate receptor modulators, mixed polymers, interferon β, monoclonal antibodies, pyrimidine synthesis inhibitors, and others. By route of administration the market is divided into oral and injectable. By distribution channels, the market is further categorized into retail pharmacies, e-commerce, and hospital pharmacies.

Regional Segmentation

Based on geography, the global multiple sclerosis drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

Multiple Sclerosis Drugs Market (North America and Europe)

North America and Europe regions dominated the global MS drugs market in the year 2018 and are expected to continue its trend throughout the forecast period 2019 – 2026. The Americas and European zone have various government organizations involved in the treatment for patients suffering from Multiple Sclerosis. Therefore, a large number of research & development activities are being carried around in these regions.

U.S. Multiple Sclerosis Drugs Market:

The US held for the majority of the share in the North America region, owing to the presence of potential drug candidates and their expected approvals. In addition, various government organizations involved in MS are partnering with many regional and local firms to spread awareness regarding the disease. Recent Trends: For instance, on Nov 18, 2019 – the National Multiple Sclerosis Society (U.S.) partnered with RealTalk MS – a popular podcast that informs and explains lots of aspects about the Multiple Sclerosis disease. The weekly podcast explores information about issues that matter to the MS community including the latest MS research, healthcare information, and legislative policy issues. The podcast also profiles people working to make life better for people with MS. Moreover, on Oct 23, 2019 – The Multiple Sclerosis Association of America (MSAA) and Novartis AG joined forces with Emmy Award-winning television celebrity and multiple sclerosis (MS) advocate Montel Williams. The educational platform aims to improve awareness about MS disease progression and secondary progressive MS (SPMS) and highlights the need for early symptom identification.

UK Multiple Sclerosis Drugs Market:

The UK MS Drugs market is also on a boom in terms of revenue. The market for the UK is growing owing to the active government regulations and rising healthcare expenditure on multiple sclerosis drugs. Recent Trends: On Oct 25, 2019 – Multiple Sclerosis Society (UK) and with the British Council to fund a new collaboration between researchers from Cambridge and Israel to investigate the effects of brain stiffening on myelin repair. The research will focus on special stem cells in the brain called oligodendrocyte precursor cells (OPCs) that are able to produce myelin-making cells. OPCs are important for repairing myelin – the fatty coating that surrounds our nerves and is damaged in MS. Further, on July 30, 2019 – the Multiple Sclerosis Society (UK) funded £1.5 million for the MS Society Tissue Bank. This tissue bank allows people to donate their brain and spinal cord tissue for MS research after their death. It's the biggest collection of MS brain and spinal cord tissue in Europe and has sent over 20,000 tissue samples out to researchers across the world.

Competitive landscape

Key players operating in the multiple sclerosis drugs industry include GlaxoSmithKline, Novartis AG, Gw Pharmaceuticals, Innate Immunotherapeutics, Genzyme, Genmab, Artielle Immunotherapeutics, Apitope, Five Prime Therapeutics, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics, Cinnagen, and Bayer AG among others. Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a encouraging opinion for Mayzent (siponimod) for the treatment of adult patients with secondary-progressive multiple sclerosis (SPMS) with active disease proved by relapses or imaging features of inflammatory activity (i.e. Gd-enhancing T1 lesions or active, new or enlarging, T2 lesions).

Multiple Sclerosis Drugs Market Key Segments:

By Drug Class

• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• Interferon β
• Monoclonal Antibodies
• Pyrimidine Synthesis Inhibitors
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channels

• Retail Pharmacies
• E-Commerce
• Hospital Pharmacies

By Geography

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • U.K
  • Germany
  • France
  • Italy
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • GCC Countries
  • Egypt
  • South Africa
  • Rest of Middle East & Africa